|From: luvb2b (Rep: 2098)||Date: 03/26/2019 10:23|
|Forum: Aldeyra Therapeutics, Inc - Msg #35||Thread #674072366 (Rec: 0) |
|listening to morning presentation for aldx. it sounds like there is substantial upside due to large patient populations and lack of recent advances in therapy. they're talking about 30m affected in the usa alone. i'm sure that there won't be 30m consumers of the drug, but just saying that there is a large patient population that is somewhat underserved by existing therapies.|
a few years ago allergan acquired an in-development dry eye program for 125m. aldx will be starting a phase 3 trial for dry eye first half of this year and current market cap is under 300m with 100m in cash. just saying this does not seem properly valued.
"There are those who market trades, and there are those who trade markets.
There are those who follow marketers, and those who follow markets.
The marketers feast on their followers; the traders feast on the markets." -luvb2b
***Disclaimer & Disclosure***: I make no guarantee as to the accuracy or validity of information in this message. Messages posted reflect my own opinions and/or those of others, and are posted for entertainment purposes only. My messages should not be construed as investment advice. Always make investment decisions in consultation with your own financial advisor. Daytrading is not suitable for everyone. You trade at your own risk. Daytrading involves considerable risk and could result in significant losses, including losses in excess of invested capital. Any information posted here is meant for entertainment purposes only and should not be assumed to be accurate. It is expected that the readers of this information do their own research and due diligence when making trading or investment decisions. I may have long or short positions in any of the stocks that are mentioned, and these positions may change at any time.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.